Expression of urokinase-type plasminogen activator receptor in hepatocellular carcinoma

Hepatology

Volumn 25, Issue 4, 1997, Pages 856-861

  Morita, Yasushi ^a   Hayashi, Yoshitake ^a   Wang, Yao ^b   Kanamaru, Taichi ^a   Suzuki, Satoshi ^a   Kawasaki, Kentaro ^a   Ohta, Kyosuke ^a   Yamamoto, Masahiro ^a   Saitoh, Yoichi ^a   Itoh, Hiroshi ^a   Doe, William F ^b  

^a KOBE UNIVERSITY   (Japan)

^b Biology and Environment   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMINOGEN ACTIVATOR; UROKINASE;

ARTICLE; CLINICAL ARTICLE; GENE EXPRESSION; HEPATITIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER METASTASIS; NORTHERN BLOTTING; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; STATISTICAL ANALYSIS; TUMOR CELL CULTURE; TUMOR RECURRENCE;

ANTIGENS, NEOPLASM; CARCINOMA, HEPATOCELLULAR; GENE EXPRESSION; HUMANS; IN SITU HYBRIDIZATION; LIVER NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; RECEPTORS, CELL SURFACE; RNA, MESSENGER; RNA, NEOPLASM; URINARY PLASMINOGEN ACTIVATOR;

EID: 0030915291     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.510250412     Document Type: Article

References (25)

1. Kenmochi K, Sugihara S, Kojiro M. Relationship of histologic grade of hepatocellular carcinoma (HCC) to tumor size, and demonstration of tumor cells of multiple different grade in single HCC. Liver 1987;7:18-26.
2. Tanaka J, Tobe T, Morino T, Arii S, Minematsu S. Clinicopathological features of malignancy in hepatocellular carcinoma. Cancer Chemother Pharmacol 1989;23(suppl):96-100.
3. Ruiz J, Sangro B, Cuende JI, Beloqui I, Riezu-Boj JI, Herrero JI, Prieto J. Hepatitis B and C viral infections in patients with hepatocellular carcinoma. HEPATOLOOY 1992;16:637-641.
4. Oda T, Tsuda H, Scarpa A, Sakamoto M, Hirohashi S. Mutation pattern of the p53 gene as a diagnostic marker for multiple hepatocellular carcinoma. Cance Res 1992;52:3674-3678.
5. Okuda K, Tanaka M, Nakayama T, Nakayama T, Saitsu H, Tanikawa K, Nakashima O, et al. Clinicopathologic comparison between resected hepatocellular carcinoma (HCC) and recurrent tumors. Int Hepatology Commun 1993;1:65-71.
6. Kosuge T, Takayama T, Yamamoto J, Shimada K, Yamasaki S. Intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. Surgery 1995;57:1306-1309.
7. Yamanaka N, Okamoto E, Toyosaka A, Mitsunobu M, Fujihara S, Kato T, Fujimoto J, et al. Prognostic factors after hepatectomy for hepatocellular carcinoma. Cancer 1990;65:1104-1110.
8. Arii S, Tanaka J, Yamazoe Y, Minematsu S, Morino T, Fujita K, Maetani S, et al. Predictive factors for intrahepatic recurrence of hepatocellular carcinoma after partial hepatectomy. Cancer 1992;69:913-919.
9. Okamoto E, Furukawa K, Yamanaka N. Prognosis after hepatectomy for hepatocellular carcinoma. Surgical Therapy 1995;73:525-533.
10. Liotta LA, Rao CN, Wewer UM. Biochemical interactions of tumor cells with the basement membrane. Annu Rev Biochem 1986;55:1037-1057.
11. Nakajima M, Chop AM. Tumor invasion and extracellular matrix degradative enzyme: regulation of activity by organ factors. Semin Cancer Biol 1991;2:115-127.
12. Tryggvason K, Höyhtyä M, Salo T. Proteolytic degradation of extracellular matrix in tumor invasion. Biochim Biophys Acta 1987;907:191-217.
13. Liotta LA, Steeg PS, Steuer-Stevenson WG. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 1991;64:327-336.
14. Wagner SN, Atkinson MJ, Thanner S, Wagner C, Schmitt M, Wilheim O, Rotter M, et al. Modulation of urokinase and urokinase receptor gene expression in human renal cell carcinoma. Am J Pathol 1995;147:183-192.
15. Nielsen BS, Sehested M, Timshel S, Pyke C, Dano K. Messenger RNA for urokinase plasminogen activator is expressed in myofibroblasts adjacent to cancer cells in human breast cancer. Lab Invest 1996;74:168-177.
16. Pyke C, Kristensen P, Ralfkiær E, Eriksen J, Dano K. Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Am J Pathol 1991;138:1059-1067.
17. Komoriya A, Hortsch M, Meyers C. Biologically active synthetic fragments of epidermal growth factor: localization of major receptor-binding region. Proc Natl Acad Sci U S A 1984;81:1351-1355.
18. Nielsen LS, Hamsen JG, Skriver L, Wilson EL, Kalfoft K, Zenthen J, Dano K. Purification of zymogen to plasminogen activator from human glioblastoma cells by affinity chromatography with monoclonal antibody. Biochemistry 1982;21:6410-6415.
19. Danø K, Andreasen PA, Grøndahl-Hansen J, Kristensen P, Nielsen LS, Skriver L. Plasminogen activators, tissue degradation and cancer. Adv Cancer Res 1985;44:139-266.
20. Foekens JA, Schmidtt M, van Putten WLJ, Peters HA, Bontenbal M, Jänicke F, Klijn JGM. Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res 1992;52:6101-6105.
21. Hasui Y, Marutsuka K, Suzumiya J, Kitada S, Osada Y, Sumiyoshi A. The content of urokinase-type plasminogen activator antigen as a prognostic factor in urinary bladder cancer. Int J Cancer 1992;50:871-873.
22. Ganesh S, Verspaget HW, Sier CFM, Vloedgraven HJM, Griffioen G, Verheijen JH, Lamers CBHW. Prognostic relevance of mucosal plasminogen activator levels in colorectal cancer. Fibrinolysis 1992;6(suppl):103.
23. Hollas W, Blasi F, Boyd D. Role of urokinase receptor in facilitating extracellular matrix invasion by cultured colon cancer. Cancer Res 1991;51:3690-3695.
24. Vassalli JD, Baccino D, Belin D. A cellular binding site for the Mr55000 form of human plasminogen activator, urokinase. J Cell Biol 1985;100:86-92.
25. Stoppelli MP, Tacchelti C, Cubellins MV. Autocrine saturation of prourokinase receptors on human A431 cells. Cell 1986;45:675-684.